Kan N, Ohgaki K, Okino T, Nakanishi M, Nio Y, Inoue K, Tobe T
1st Dept. of Surgery, Kyoto University, Faculty of Medicine.
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):755-62.
Two immunotherapeutic methods were developed as adjuvant therapy for gastrointestinal malignancies, one using oral administration of a streptococcal preparation, OK-432, and the other with adoptive immunotherapy (AIT), local transfer of IL2-cultured and autologous lymphocytes, combined with local preadministration of OK-432. Tsuchitani and Nio in our laboratory have revealed experimentally that oral OK-432 stimulates tumor-specific and non-specific immune mechanisms of gut-associated lymphoid tissues and inhibits the growth of some murine syngeneic tumors that were transplanted into cecal patches. The clinical efficacy of oral OK-432 on gastric cancer patients has been examined by a controlled randomized trial involving a total of about 1000 cases. Oral OK-432 (5KE, once a week) was revealed to be significantly effective in curatively resected group but not effective in non-curatively resected group. Ten consecutive patients with peritoneal dissemination of gastric cancer were treated with intraperitoneal OK-432 and AIT. AIT was performed by transferring autologous lymph node-lymphocytes cultured for 13 days with crude IL2 and tumor-extract. The survival of the treated patients was significantly longer (50% survival period exceeded 1 year) than that of historical control (95 cases, 50% survival period was 5 months). These immunotherapeutic methods are expected to be useful for multidisciplinary therapy of gastric cancer by a combination of each method with other therapeutic methods.
两种免疫治疗方法被开发用于胃肠道恶性肿瘤的辅助治疗，一种是口服链球菌制剂OK-432，另一种是过继性免疫疗法（AIT），即局部转移经白细胞介素-2培养的自体淋巴细胞，并联合局部预先给予OK-432。我们实验室的土谷谷和二尾通过实验发现，口服OK-432可刺激肠道相关淋巴组织的肿瘤特异性和非特异性免疫机制，并抑制移植到盲肠小块中的一些小鼠同基因肿瘤的生长。通过一项涉及约1000例患者的对照随机试验，研究了口服OK-432对胃癌患者的临床疗效。结果显示，口服OK-432（5KE，每周一次）在根治性切除组中具有显著疗效，但在非根治性切除组中无效。连续10例胃癌腹膜播散患者接受了腹腔内注射OK-432和AIT治疗。AIT是通过转移用粗制白细胞介素-2和肿瘤提取物培养13天的自体淋巴结淋巴细胞来进行的。治疗患者的生存期明显长于历史对照组（95例，50%生存期为5个月）（50%生存期超过1年）。这些免疫治疗方法有望通过将每种方法与其他治疗方法相结合，用于胃癌的多学科治疗。
